OrbiMed Raises $3 Billion Across Global and Asia Healthcare Funds

By Grace Kim

OrbiMed has raised $3 billion across a global healthcare fund and an Asia-focused vehicle, according to a report by Pulse 2.0. The dual raise lands at a moment when healthcare fundraising has been anything but easy, which makes the $3 billion figure the number worth watching.

OrbiMed is one of the most established names in healthcare-only investing. The firm backs companies across the sector's full span — from biopharma and medical devices to healthcare services — at stages running from early venture through growth and public markets.

The new capital sits in two pools. One targets healthcare opportunities globally. The other is dedicated to Asia, a region where OrbiMed has been building out its presence for years through offices and dedicated investment teams.

Why split the raise between global and Asia?

Pulse 2.0's report frames the $3 billion as spread across the two vehicles rather than concentrated in one. That structure signals where OrbiMed sees demand from its limited partners and where it expects to deploy.

Asia's healthcare markets keep scaling on the back of aging populations, expanding middle-class spending on care, and a deepening pipeline of local drug development. A dedicated Asia fund lets OrbiMed price those opportunities separately from its global book — and lets investors choose their exposure.

The global vehicle, by contrast, gives the firm dry powder for the United States, Europe, and any market that clears its bar. In effect, OrbiMed is running two theses off one platform.

What does $3 billion buy in this market?

It buys patience. Healthcare investing runs on long development cycles — a drug candidate can take a decade from lab to market — so capital raised today is capital deployed over years, not quarters.

It also buys position. A $3 billion war chest lets OrbiMed lead large rounds, defend ownership stakes in follow-on financings, and move when rivals pull back. In a period when many firms have slowed their pacing, fresh capital of this size shifts leverage toward the investor holding it.

The raise also says something about limited partners. Raising $3 billion means institutions — pensions, endowments, sovereign funds — wrote checks for healthcare exposure at a time when the broader private-equity fundraising environment has been tight.

Who is OrbiMed?

The firm has operated for decades as a healthcare-specialist investor, with a team that includes scientists, physicians, and industry operators alongside traditional investors. Its portfolio spans the sector's main categories, and it has backed companies from startup stage through public listings.

OrbiMed's Asia practice is a core part of the platform rather than a satellite. The firm has invested across the region's major healthcare markets and runs local teams focused on local deals — the kind of setup a $3 billion split raise is designed to feed.

What comes next?

The capital now has to find a home. Expect OrbiMed to put the two funds to work across biotech financing, medical technology, and healthcare services deals, with the Asia vehicle steering toward the region's fastest-growing care markets.

For founders and research institutions in both geographies, a fully charged OrbiMed means one more deep-pocketed, sector-only investor answering the phone.

The takeaway: $3 billion is a bet that healthcare's long cycles reward whoever shows up with capital and patience.